The information gained from the initial pilot study will be incorporated into this study design to further characterize the mechanism of lymphocyte renewal and to increase the number of patients observed. Only minor modifications to the pilot protocol are proposed including the sample size, addition of volunteers not receiving therapy, and a double-blind design: Ten (10) HIV-1 infected patients will be dosed with PROLASTIN®-C (Grifols Therapeutics Inc.), five (5) will be dosed with placebo, and five (5) uninfected volunteers not receiving therapy will be monitored.